Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lok, Gabriel T M ^a   Chan, David W ^a   Liu, Vincent W S ^a   Hui, Winnie W Y ^a   Leung, Thomas H Y ^a   Yao, K M ^a   Ngan, Hextan Y S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR M1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; THIOSTREPTON; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; ENZYME INHIBITOR; FOXM1 PROTEIN, HUMAN; GELATINASE B; ISOPROTEIN; NITRILE; PHOSPHOPROTEIN; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; OVARY CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; CELL LINE; CELL MOTION; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BUTADIENES; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NITRILES; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROTEIN ISOFORMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIOSTREPTON; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051723542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023790     Document Type: Article

References (40)

1. Holschneider CH, Berek JS, (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10.
2. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
3. Wierstra I, Alves J, (2007) FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388: 1257-1274.
4. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, et al. (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136.
5. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, et al. (2001) Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 507: 59-66.
6. Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, et al. (2008) Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol 215: 245-252.
7. Liu M, Dai B, Kang SH, Ban K, Huang FJ, et al. (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66: 3593-3602.
8. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, et al. (2002) FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773-4780.
9. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH, (2007) Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300.
10. Frau M, Biasi F, Feo F, Pascale RM, (2010) Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 31: 179-193.
11. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, et al. (2006) Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66: 1712-1720.
12. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, et al. (2009) FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 4: e4849.
13. Laoukili J, Stahl M, Medema RH, (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102.
14. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, et al. (2006) The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66: 2153-2161.
15. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, et al. (2008) FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res 68: 8733-8742.
16. Park HJ, Gusarova G, Wang Z, Carr JR, Li J, et al. (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3: 21-34.
17. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
18. Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, et al. (2008) Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29: 1742-1750.
19. Liao YC, Shih YW, Chao CH, Lee XY, Chiang TA, (2009) Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J Agric Food Chem 57: 8933-8941.
20. Neill GW, Harrison WJ, Ikram MS, Williams TD, Bianchi LS, et al. (2008) GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes. Carcinogenesis 29: 738-746.
21. Chen H, Zhu G, Li Y, Padia RN, Dong Z, et al. (2009) Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 69: 9228-9235.
22. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, et al. (2005) Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 118: 795-806.
23. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, et al. (2009) Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 58: 679-687.
24. Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, et al. (2006) The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem 281: 25167-25176.
25. Yoshida Y, Wang IC, Yoder HM, Davidson NO, Costa RH, (2007) The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132: 1420-1431.
26. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, et al. (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7: 2022-2032.
27. Raj D, Liu T, Samadashwily G, Li F, Grossman D, (2008) Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29: 194-201.
28. Barsotti AM, Prives C, (2009) Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28: 4295-4305.
29. Innocente SA, Lee JM, (2005) p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 579: 1001-1007.
30. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, et al. (2006) Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 281: 25134-25142.
31. Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, et al. (2010) Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 36: 151-156.
32. Wang IC, Chen YJ, Hughes DE, Ackerson T, Major ML, et al. (2008) FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem 283: 20770-20778.
33. Ahmad A, Wang Z, Kong D, Ali S, Li Y, et al. (2010) FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 122: 337-346.
34. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
35. Steinmetz R, Wagoner HA, Zeng P, Hammond JR, Hannon TS, et al. (2004) Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18: 2570-2582.
36. Halasi M, Gartel AL, (2009) A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8: 1966-1967.
37. Bhat UG, Zipfel PA, Tyler DS, Gartel AL, (2008) Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle 7: 1851-1855.
38. Bhat UG, Halasi M, Gartel AL, (2009) Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 4: e5592.
39. Bhat UG, Halasi M, Gartel AL, (2009) FoxM1 is a general target for proteasome inhibitors. PLoS One 4: e6593.
40. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, et al. (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8: 24-34.